Composite lipid-regulation medicine

A drug and lipid-regulating technology, applied in drug combinations, pharmaceutical formulations, plant raw materials, etc., can solve problems such as elevation, cataracts, less adverse reactions, and small drug doses, and achieve the regulation of cardiovascular function, prevention of drug damage, and absorption of drugs. high rate effect

Inactive Publication Date: 2009-07-29
王法平
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are no serious adverse reactions when statins are used in general doses for a short period of time, and a few have mild gastrointestinal reactions, headaches or rashes; however, long-term use (more than 4 weeks) often results in liver damage, myalgia, and creatine phosphokinase Cataract, especially rhabdomyolysis and renal failure, has a high fatality rate; for patients with h

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composite lipid-regulation medicine
  • Composite lipid-regulation medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] Embodiment one: preparation of sugarcane extract

[0049] Get sugarcane wax, melt in advance, use 10 to 20% concentrated sodium hydroxide, calcium hydroxide or potassium hydroxide solution saponification 3 to 10 hours of wax weight in homogeneous phase, then use organic solvent (such as n-hexane, acetone, Methyl ethyl ketone, methanol, ethanol, isopropanol, chloroform, dichloromethane, 1,2-dichloroethane, benzene, toluene or their mixtures) selectively extract alcohol mixtures in a solid-liquid extraction system , extracted for a total of 15 to 20 hours, and then recrystallized in the above-mentioned solvent or their mixture to obtain the sugarcane extract, which is a kind of off-white or light yellow powder crystal, which is policosanol with 24 to 34 carbon atoms, Accounting for more than 90% of the total extract weight, among which the content of octacosanol is the highest, which is 60%-70%; tetracosanol is about 2%, hexacosanol is about 4.52%-10%, heptacosane Alcoho...

example 2

[0050] Example 2: Tingcane Capsules

[0051] 1. Specification: 10mg

[0052] 2. Prescription:

[0053] Pitavastatin 1.0g

[0054] Sugarcane extract (contains more than 90% policosanol) 9.0g

[0055] Lactose 60.0g

[0056] Sodium bicarbonate 12.0g

[0057] Croscarmellose Sodium 1.5g

[0058] 2% hypromellose 30% ethanol solution appropriate amount

[0059] Silica 1.5g

[0060] Magnesium stearate 0.4g

[0061] Makes 1000 capsules

[0062] 3. Preparation process

[0063] (1) Preparation of adhesive: take hypromellose by weighing and dissolve in purified water, add appropriate amount of ethanol, dilute into 2% hypromellose 30% ethanol solution, set aside;

[0064] (2) Processing of excipients: Pass lactose, croscarmellose sodium, and sodium bicarbonate through a 100-mesh sieve respectively, and weigh the prescription amount for subsequent use;

[0065] (3) Mixing: after pitavastatin and policosanol pass through a 120-mesh sieve, weigh the prescription amount, and mix wit...

example 3

[0077] Example 3: Tingcane Tablets

[0078] 1. Specification: 10mg

[0079] 2. Tablet core prescription:

[0080] Pitavastatin 1.0g

[0081] Sugarcane extract (contains more than 90% policosanol) 10.0g

[0082] Lactose 73.6g

[0083] Croscarmellose Sodium 3.2g

[0084] Sodium bicarbonate 8.5g

[0085] Silica 1.6g

[0086] Talc powder 1.6g

[0087] Magnesium stearate 0.5g

[0088] 2% hypromellose appropriate amount

[0089] 50% ethanol solution appropriate amount

[0090] Makes 1000 pieces

[0091] 3. Preparation process

[0092] (1) Preparation of adhesive: take hypromellose by weighing and dissolve in purified water, add appropriate amount of ethanol, dilute into 2% hypromellose 50% ethanol solution, set aside;

[0093] (2) Processing of excipients: Pass lactose, 1 / 2 croscarmellose sodium, and sodium bicarbonate through a 100-mesh sieve respectively, and weigh the prescription amount for later use;

[0094] (3) Mixing: after pitavastatin and policosanol pass thro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a medicine with lipid-regulating function, in particular to a medicine for treating hyperlipoidemia or atherosclerosis. The medicine comprises a lipid-regulating active ingredient and a synergistic agent, and is characterized in that the lipid-regulating active ingredient is HMG-CoA reductase inhibitor; and the synergistic agent is cane extract. The compound lipid-regulating medicine can reduce dosage of the HMG-CoA reductase inhibitor so as to reduce toxic and side effect of the inhibitor and improve drug effect.

Description

technical field [0001] The invention relates to a medicine with lipid-lowering effect, in particular to a medicine for treating hyperlipidemia or atherosclerosis. It belongs to the field of medicine. Background technique [0002] Hyperlipidemia is the chief culprit of atherosclerosis and the main pathophysiological basis of cardiovascular and cerebrovascular diseases. Prevention and treatment of atherosclerosis is an important measure for the prevention and treatment of cardiovascular and cerebrovascular diseases. fat medicine. At present, the commonly used lipid-lowering drugs can treat hyperlipidemia and produce anti-arteriosclerosis effects by adjusting the disorder of plasma lipids or lipoproteins. The most new and effective drug is 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors, or "statins" drugs. There are no serious adverse reactions when statins are used in general doses for a short period of time, and a few have mild gastrointestinal reactions, he...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/06A61K36/899A61P3/06A61P9/10A61K31/366A61K31/47
Inventor 王法平杨迎暴
Owner 王法平
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap